Research programme: neoantigen immunotherapies - Turnstone Biologics
Alternative Names: MG1-NeoantigenLatest Information Update: 28 Oct 2022
At a glance
- Originator Turnstone Biologics
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer